NewsRoom Articles - Page 31 of 46

SundayDec 11, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Announces Collaboration with Exwayz, as Lidar is Quickly Becoming an Essential Sensor Technology Within the Robotics Sector

Autonomous robotics are increasingly being used to automate manual logistics processesIn addition to its own software solutions, Cepton collaborates with software provider Exwayz to present a robotic solution for global customersThe company recently announced that it will unveil its upcoming next-generation automotive lidar solution, the Vista-X120 Plus, at the forthcoming CES 2023 event in Las VegasAs part of that product launch, Cepton has been recently recognized as a 2023 Innovation Award honoree by CES within the vehicle tech and advanced mobility category In early June, Amazon unveiled its new fleet of autonomous robots, designed to revolutionize the way that half…

WednesdayDec 07, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research programThe program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drugThe first study evidenced that DehydraTECH-CBD is more efficacious at lower doses than EpidiolexThe second study demonstrated DehydraTECH-CBD’s enhanced effectiveness; specifically, the formulation acted more rapidly than Epidiolex Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) formulation has demonstrated performance enhancements compared to Epidiolex(R), the first and only FDA-approved CBD medication for…

FridayDec 02, 2022 9:45 am

Vision Energy Corp. (VIHDD) Develops Carbon-Reduced Solutions for Commercial, Industrial, and Transportation Industries, as It Pursues Landmark Design for First European Terminal

The European Green Deal, with the objective to become climate-neutral by 2050, implies a near-total phase-out of fossil fuels in the EU energy systemVision Energy signed a cooperation agreement with Linde Engineering to accelerate efforts for its pioneering Green Energy Terminal in the North Sea Port of Vlissingen, the NetherlandsEngineering efforts under the agreement have commenced and are anticipated to conclude in April 2023, supporting the company’s target to reach a Final Investment Decision by Q3 2023 Hydrogen presents a global opportunity to reduce greenhouse gas emissions due to its high efficiency and zero-or near-zero-emissions operation. The global hydrogen market…

FridayDec 02, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

70% of total fatalities in urban areas are vulnerable road usersAs of 2000, a U.S.-based pedestrian was involved in a fatal accident every 81 minutesIn conjunction with its technological partners, Cepton has designed a lidar-based road sensor, directed to warn drivers about potential pedestrian activity around a corner 5 seconds before they would otherwise be visibleDespite its original intended use as an advanced motion-system tool, the use of lidar technology has far surpassed its original necessitiesToday, lidar technology is being used within a wide array of initiatives and industries, ranging from security and safety solutions, smart railways, and traffic control…

WednesdayNov 30, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

70% of total fatalities in urban areas are vulnerable road users As of 2000, a U.S.-based pedestrian was involved in a fatal accident every 81 minutes In conjunction with its technological partners, Cepton has designed a lidar-based road sensor, directed to warn drivers about potential pedestrian activity around a corner 5 seconds before they would otherwise be visible Despite its original intended use as an advanced motion-system tool, the use of lidar technology has far surpassed its original necessities Today, lidar technology is being used within a wide array of initiatives and industries, ranging from security and safety solutions, smart…

TuesdayNov 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at…

MondayNov 28, 2022 9:00 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastomaCNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in FranceCNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patientsThe company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 The FDA has granted Berubicin Fast Track…

WednesdayNov 23, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementiaThe animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancementsPrevious independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairmentThe laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023 Lexaria Bioscience (NASDAQ:…

TuesdayNov 22, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumorsCNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBMBerubicin is a novel anthracycline and the first to appear to cross the blood-brain barrierThe global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage…

MondayNov 21, 2022 11:15 am

Cepton, Inc. (NASDAQ: CPTN) to Solidify Its Financial Position With $100 Million Investment from Koito; Forges Ahead Toward Mass-Market Deployment of Its Lidar Technology

Cepton signed binding agreement with established automotive lighting tier 1 supplier Koito for investment of $100 million to bolster its next stage of growthAgreement penned on October 27, 2022, marks the third investment from this long-term automotive Tier 1 partner and existing shareholder since 2020Lidar market expected to grow rapidly to reach $59 billion by 2030; Cepton appears to continue leading as a prominent figure, as it works toward commercialization and mass market deployment of its lidar sensors Following a previously reported letter of intent from Koito Manufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it has entered…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Cepton, Inc. (NASDAQ: CPTN) Announces Collaboration with Exwayz, as Lidar is Quickly Becoming an Essential Sensor Technology Within the Robotics Sector

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

Vision Energy Corp. (VIHDD) Develops Carbon-Reduced Solutions for Commercial, Industrial, and Transportation Industries, as It Pursues Landmark Design for First European Terminal

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

Cepton, Inc. (NASDAQ: CPTN) to Solidify Its Financial Position With $100 Million Investment from Koito; Forges Ahead Toward Mass-Market Deployment of Its Lidar Technology

TinyGems

Quote / Research

Site Search